Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.
BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.
San Diego's BioNano Genomics has raised a $53 million C round to bankroll its efforts to decode the so-called inaccessible genome, adding Novartis to its investor syndicate as it works to amplify its profile.
U.K. biotech investment heavyweight Neil Woodford has invested $25 million in the U.S. biotech Northwest Biotherapeutics, gambling that its controversial Phase III study on a new therapeutic vaccine for brain cancer comes up a winner.
In what will likely be the most closely watched IPO in biotech, Juno Therapeutics has rolled out a $150 million offering that is likely to make a big splash on the market.
Third Rock Ventures startup Blueprint Medicines has hauled in a $50 million C round, cash that'll see its way through clinical trials and keep its promising platform generating new candidates.
Two years after Michael Yeadon and a close-knit group of Pfizer investigators managed to grab some of the pharma giant's anti-inflammatory assets on the way out the door at Sandwich, they've drummed up a $33 million B round for their biotech from some U.S. and European investors. And now they're set to launch a midstage clinical program to help determine the value of what they took with them when launching Ziarco.
New Haven, CT's Trevi Therapeutics banked another $11 million in venture cash, bringing its B round to $26 million and giving it the cash it needs to complete a pivotal trial for its top prospect.
Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $22.4 million in total as it prepares to take its expirimental marrow cancer treatment into late-stage development.
Having spent the past 10 months weighing up the merits of a separate listing for its IT subsidiary NNIT, Novo Nordisk has decided it needs to wait a little longer before pulling the trigger.